Diphtheria Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Funding
• Alerts
• Clinical Trials
• Forums

Double Blind, Randomized Phase III Study to Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children
Conditions:   Diphtheria;   Tetanus Interventions:   Biological: BR-TD-1001;   Biological: Td-pur inj Sponsor:   Boryung Biopharma Co., Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 6, 2020 Category: Research Source Type: clinical trials

To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years
Conditions:   Diphtheria;   Tetanus;   Pertussis;   Poliomyelitis Intervention:   Biological: DTaP-IPV combination vaccine Sponsor:   Boryung Biopharma Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 6, 2020 Category: Research Source Type: clinical trials

Double Blind, Randomized Phase III Study to Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children
Conditions:   Diphtheria;   Tetanus Interventions:   Biological: BR-TD-1001;   Biological: Td-pur inj Sponsor:   Boryung Biopharma Co., Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 6, 2020 Category: Research Source Type: clinical trials

To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years
Conditions:   Diphtheria;   Tetanus;   Pertussis;   Poliomyelitis Intervention:   Biological: DTaP-IPV combination vaccine Sponsor:   Boryung Biopharma Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 6, 2020 Category: Research Source Type: clinical trials

Double Blind, Randomized Phase III Study to Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children
Conditions:   Diphtheria;   Tetanus Interventions:   Biological: BR-TD-1001;   Biological: Td-pur inj Sponsor:   Boryung Biopharma Co., Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 6, 2020 Category: Research Source Type: clinical trials

To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years
Conditions:   Diphtheria;   Tetanus;   Pertussis;   Poliomyelitis Intervention:   Biological: DTaP-IPV combination vaccine Sponsor:   Boryung Biopharma Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 6, 2020 Category: Research Source Type: clinical trials

Double Blind, Randomized Phase III Study to Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children
Conditions:   Diphtheria;   Tetanus Interventions:   Biological: BR-TD-1001;   Biological: Td-pur inj Sponsor:   Boryung Biopharma Co., Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 6, 2020 Category: Research Source Type: clinical trials

To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years
Conditions:   Diphtheria;   Tetanus;   Pertussis;   Poliomyelitis Intervention:   Biological: DTaP-IPV combination vaccine Sponsor:   Boryung Biopharma Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 6, 2020 Category: Research Source Type: clinical trials

Double Blind, Randomized Phase III Study to Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children
Conditions:   Diphtheria;   Tetanus Interventions:   Biological: BR-TD-1001;   Biological: Td-pur inj Sponsor:   Boryung Biopharma Co., Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 6, 2020 Category: Research Source Type: clinical trials

To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years
Conditions:   Diphtheria;   Tetanus;   Pertussis;   Poliomyelitis Intervention:   Biological: DTaP-IPV combination vaccine Sponsor:   Boryung Biopharma Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 6, 2020 Category: Research Source Type: clinical trials

Double Blind, Randomized Phase III Study to Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children
Conditions:   Diphtheria;   Tetanus Interventions:   Biological: BR-TD-1001;   Biological: Td-pur inj Sponsor:   Boryung Biopharma Co., Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 6, 2020 Category: Research Source Type: clinical trials

To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years
Conditions:   Diphtheria;   Tetanus;   Pertussis;   Poliomyelitis Intervention:   Biological: DTaP-IPV combination vaccine Sponsor:   Boryung Biopharma Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 6, 2020 Category: Research Source Type: clinical trials

Double Blind, Randomized Phase III Study to Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children
Conditions:   Diphtheria;   Tetanus Interventions:   Biological: BR-TD-1001;   Biological: Td-pur inj Sponsor:   Boryung Biopharma Co., Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 6, 2020 Category: Research Source Type: clinical trials

To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years
Conditions:   Diphtheria;   Tetanus;   Pertussis;   Poliomyelitis Intervention:   Biological: DTaP-IPV combination vaccine Sponsor:   Boryung Biopharma Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 6, 2020 Category: Research Source Type: clinical trials

Double Blind, Randomized Phase III Study to Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children
Conditions:   Diphtheria;   Tetanus Interventions:   Biological: BR-TD-1001;   Biological: Td-pur inj Sponsor:   Boryung Biopharma Co., Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 6, 2020 Category: Research Source Type: clinical trials